NCT00147121

Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV Low-grade B-cell Lymphoma (JCOG0203)

Rituximab + Standard CHOP (R･S-CHOP) vs Rituximab+ Bi-weekly CHOP (R･Bi-CHOP) RCT(Phase II/III) for Stage III/IV Low-grade B-cell Lymphoma (LowBNHL-RS/BiCHOP-P2/3) (JCOG0203)

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 300 (actual)
• Sponsor: Haruhiko Fukuda · Academic / Other
• Sex: All
• Age: 20 Years – 69 Years
• Healthy volunteers: Not accepted

Summary

To establish standard therapy for patients with advanced-stage low grade B-cell lymphoma

Detailed description

Since currently there is no standard therapy for untreated advanced-stage low-grade B-cell lymphoma, Phase 2/3 study was planned. Comparison(s): An intensified bi-weekly version by shortening the intervals of both rituximab and CHOP therapies using G-CSF, compared to the tri-weekly R-CHOP regimen.

Conditions

• Lymphoma, B-Cell

Interventions

Type	Name	Description
DRUG	Rituximab + Standard CHOP	Rituximab + Standard CHOP
DRUG	Rituximab + Bi-weekly CHOP	Rituximab + Bi-weekly CHOP

Timeline

• Start date: 2002-09-01
• Primary completion: 2010-02-01
• Completion: 2010-02-01
• First posted: 2005-09-07
• Last updated: 2016-09-22

Locations

45 sites across 1 country: Japan